Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cardiovascular disease

Ischemia/reperfusion injury

Adenosine A2B receptor (ADORA2B)

Patient sample and mouse studies suggest agonizing ADORA2B could help prevent ischemia and reperfusion injury during liver transplant. In liver biopsies obtained from patients undergoing liver transplant, ADORA2B levels were higher after ischemia and reperfusion. In mice undergoing liver ischemia and reperfusion, pretreatment with an ADORA2B agonist decreased liver injury and inflammation compared with vehicle pretreatment. Next steps include identifying alternative ADORA2B agonists for human disease.
Gilead Sciences Inc. and Astellas Pharma Inc., market the ADORA2A agonist Lexiscan regadenoson as a cardiovascular imaging agent.
Adenosine Therapeutics LLC's ADORA2A agonist, Stedivaze apadenoson, is in Phase III testing as a cardiovascular imaging agent.
Swedish Orphan Biovitrum AB's BVT.115959, an ADORA2A agonist, is in Phase II to treat pain.

SciBX 6(30); doi:10.1038/scibx.2013.793
Published online Aug. 8, 2013

Unpatented; licensing status not applicable

Zimmerman, M.A. et al. Proc. Natl. Acad. Sci. USA; published online
June 28, 2013;
doi:10.1073/pnas.1221733110
Contact: Holger K. Eltzschig, University of Colorado Denver, Aurora, Colo.
e-mail:
holger.eltzschig@ucdenver.edu